Broth Culture Testing for Interstitial Cystitis
Customize your policy alerts
Sign up for Aetna Policy 0695 alerts
Get alerted when Policy 0695 changes without checking for updates manually.
Monitor payer policy activity
This policy governs the use and coverage stance for broth culture testing intended to diagnose or manage interstitial cystitis and applies to Aetna members and participating providers.
No material clinical or coverage changes in this revision.
Coverage Criteria
Experimental and Investigational
From policy statement
Aetna considers broth culture testing for interstitial cystitis to be experimental and investigational because there is inadequate evidence that the test is effective for the diagnosis or management of interstitial cystitis. The policy specifically lists the ICD-10 codes N30.10–N30.11 (interstitial cystitis, chronic) in association with this coverage stance.
Because the peer-reviewed evidence does not demonstrate clinical benefit for broth culture methods in this indication, the procedure is labeled investigational and is not supported for routine clinical use in members with suspected or diagnosed interstitial cystitis. As a result, claims for broth culture testing performed for this indication may be denied as not medically necessary under this policy.
Coding
Provider Actions & Billing
Experimental / Investigational — Denial Risk
Broth culture testing for interstitial cystitis is designated experimental and investigational by the payer; this designation may lead to denial of coverage for such testing.
Prior Authorization
No prior authorization requirements are specified in the source content for broth culture testing in this policy.
Step Therapy
No step therapy requirements are specified in the source content for broth culture testing in this policy.
Documentation Requirements
No documentation requirements are specified in the source content for broth culture testing in this policy.
Policy Scope
This bulletin addresses broth culture testing for interstitial cystitis and states that such testing is considered experimental and investigational; providers should be aware testing may not be covered for this indication.
Provider Actions (Reserved)
Provider action: reserved (no additional provider actions were specified in the source content).
Denial Triggers
No specific denial triggers (beyond the investigational designation) are stated in the source content.
Background
Interstitial cystitis (IC) is a chronic bladder disorder of uncertain etiology characterized primarily by urinary urgency, frequency, and bladder pain. It is generally a diagnosis of exclusion based on symptom assessment and, when used, cystoscopy or biopsy. Some investigators have proposed specialized broth culture techniques to identify bacteria not detected by standard urine cultures, but major clinical reviews and guideline bodies do not support a bacterial cause for IC and do not endorse broth culture testing for routine diagnosis or management.
Definitions
Revision History
Policy became effective.
Policy was last reviewed.
Next scheduled review date for the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.